University Lecturer; Honorary Consultant Urological Surgeon
Mr Grant Stewart is an academic urological surgeon with clinical and research expertise in kidney cancer. Clinically, Mr Stewart undertakes a full range of treatments for renal cancer at Addenbrooke’s Hospital, from robotic partial nephrectomy for small renal cancers to multi-speciality surgery for locally advanced disease.
Grant has a specific interest in optimising management of patients with initially localised renal cancer, an area of great need within the disease. In order to make practice changing developments in this area Mr Stewart has developed a range of interlinked clinical trials and translational research which are all underpinned by clinical excellence in managing renal cancer at Addenbrooke’s Hospital. To deliver on the above goals, Grant coordinates the Cambridge Renal Cancer Collaboration (CamRenCan) a group of 40 clinicians, translational researchers and basic scientists across the Cambridge Biomedical Campus with a shared interest in renal cancer research.
Mr Stewart moved to Cambridge in October 2015 from a post as Senior Lecturer in Urological Surgery at the University of Edinburgh where he led the Edinburgh Urological Cancer Group, undertaking translational research into renal cell cancer. Grant developed and co-directs the Scottish Collaboration On Translational Research into Renal Cell Cancer (SCOTRRCC), a Scotland-wide kidney cancer bio-repository with high quality clinical data linkage. Biosamples (fresh frozen, FFPE, blood, urine) have been collected from 1200 patients as part of SCOTRRCC, leveraging translational kidney cancer research across Scotland. In addition to SCOTRRCC, Mr Stewart coordinated a 387 patient prostate cancer diagnostics trial, resulting in a commercially available test in USA (ConfirmMDx).
Mr Stewart chairs the Renal Cancer Surgical Subgroup of the National Cancer Research Institute Bladder and Renal Cancer Clinical Studies Group, Co-Chair of the Renal Cross Channel Group, sits on the Medical Advisory Board for Cambridge Medical Robotics, is a member of the scientific advisory board of The Urology Foundation and is CI/PI for several renal cancer clinical trials.
Rossi H, Hsu R, Blick C, Goh V, Nathan P, Nicol D, Fleming S, Sweeting M, Wilson ECF, Stewart GD. A meta-analysis of the prevalence of renal cancer detected by abdominal ultrasonography in asymptomatic individuals. British Journal of Surgery. In press.
Stewart D, Powles T, Van Neste C, Meynert A, O’Mahony F, Laird A, Deforce D, Van Nieuwerburgh F, Trooskens G, Van Criekinge W, De Meyer T, Harrison DJ. (2016) Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer. Oncotarget. 7(18):25241-50
Stewart D, O’Mahony FC, Laird A, Eory L, Lubbock ALR, Mackay A, Nanda J, O’Donnell M, Mullen P, McNeill SA, Riddick ACP, Berney D, Bex A, Aitchison M, Overton IM, Harrison DJ, Powles T.(2015) Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer. Clinical Cancer Research. 21(18): 4212–23.
Stewart D, O’Mahony FC, Laird A, Rashid S, Martin SA, Eory L, Lubbock ALR, Nanda J, O’Donnell M, Mackay A, Mullen P, McNeill SA, Riddick ACP, Aitchison M Berney MD, Bex A, Overton IM, Harrison DJ, Powles T. (2014) Carbonic anhydrase 9 expression increases with VEGF targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. European Urology. 66: 956-963.
Sharpe K, Stewart GD (joint 1st author), Mackay A, Van Neste C, Rofe C, Berney DM, Kayani I, Bex A, Wan E, O’Mahony F, O’Donnell M, Chowdhury S, Doshi R, Ho Yen C, Gerlinger M, Baker D, Smith NR, Davies BR, Sahdev A, Boleti E, de Meyer T, Van Criekinge W, Beltran L, Lu Y-J, Harrison D, Reynolds AR, Powles T. (2013) The effect of VEGF targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clinical Cancer Research. 19: 6924-6934.
Stewart D, Van Neste L, Delvenne P, Delrée P, Delga A, McNeill SA, O’Donnell M, Clark J, Van Criekinge W, Bigley J, Harrison DJ. (2013) Clinical Utility of an Epigenetic Assay to Detect Occult Prostate Cancer in Histopathologically Negative Biopsies: Results of the MATLOC Study. Journal of Urology. 189 (3): 1110-1116.
Areas of expertise
kidney cancer, renal cell cancer, translational research, biomarker development, clinical trials, window-of-opportunity trials, neoadjuvant trials, adjuvant trials, screening, device trials.